3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
3
Completed
2
Unknown
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
52
Myelodysplastic Syndromes
25
Multiple Myeloma
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
23
Leukemia
23
Lymphoma
22
Lymphoma, Non-Hodgkin
21
Leukemia, Lymphocytic, Chronic, B-Cell
21
Melanoma
19
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
17
Neoplasms
13
Hodgkin Disease
13
Neoplasm Metastasis
12
Recurrence
11
Hematologic Neoplasms
10
Lymphoma, Large B-Cell, Diffuse
9
Skin Neoplasms
8
Neoplasms, Plasma Cell
8
Myeloproliferative Disorders
8
Lymphoma, Mantle-Cell
8
Lymphoma, Follicular
8
Lymphoma, B-Cell
8
Kidney Neoplasms
8
Ovarian Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Burkitt Lymphoma
7
Carcinoma, Renal Cell
6
Triple Negative Breast Neoplasms
5
Primary Myelofibrosis
5
Anemia, Refractory, with Excess of Blasts
5
Interventions
Lenalidomide
5
Rituximab
4
Brentuximab Vedotin
4
Vincristine
3
Etoposide
3
Cyclophosphamide
3
romidepsin
2
Vorinostat
2
Granulocyte Colony-Stimulating Factor
2
Gemcitabine
2
Doxorubicin
2
Dasatinib
2
tislelizumab
1
selinexor
1
plerixafor
1
pembrolizumab
1
pegfilgrastim
1
parsaclisib
1
obinutuzumab
1
obatoclax
1
monomethyl auristatin E
1
liposomal doxorubicin
1
ixazomib
1
idelalisib
1
ibrutinib
1
gemcitabine-oxaliplatin regimen
1
fludarabine
1
etoposide phosphate
1
denileukin diftitox
1
copanlisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, T-Cell, Peripheral
×
fludarabine
×
Clear all
NCT05883449
2025-08-20
LuminICE-203
Affimed GmbH
Phase 2
Terminated
25 enrolled
21 charts